Corticosteroid-Related Adverse Events in Patients with Giant Cell Arteritis: A Claims-Based Analysis

Gordon H. Sun, MD, MS; Khaled Sarsour, PhD, MPH; Eunice Chang, PhD; Michael S. Broder, MD, MSHS; Neil Collinson, PhD; Katie Tucklew, PhD; Pavel Napalkov, MD; Micki Kleieran, MD

Partnership for Health Analytic Research, LLC, Beverly Hills, CA, United States; Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, United States; Roche Products Ltd, Welwyn Garden City, AL7 United Kingdom.

RESULTS

By adjusting for patient characteristics, we found that a 1-year increase in cumulative prednisone-equivalent exposure increased the hazard ratio of developing a first adverse event by 3% (p < .001) in this cohort. The hazard ratio of adverse events was 1.05 (95% CI 1.02-1.09) with 12 g of cumulative prednisone-equivalent exposure (Figure 3).

Figure 3. Relationship between corticosteroid exposure within 1 year of diagnosis of developing oral corticosteroid-related adverse events.

CONCLUSIONS

We found that with increasing oral corticosteroid exposure, the risk of developing oral corticosteroid-related adverse events increased. By multiple measures, high-dose oral CS use was associated with a significantly increased risk of oral corticosteroid-related adverse events.

DISCLOSURES

Michael S. Broder, is an employee of Partnership for Health Analytic Research, LLC; Pavel Napalkov, MD, is a consultant to Genentech, Inc., a member of the Roche Group; Neil Collinson, PhD, has received travel expenses and compensation for participation in consultancies from Genentech Inc. and Genzyme Corporation; Katie Tucklew, PhD has received compensation for participation in a consultancy and for participation in the Genentech Rentoul Grant Program; Eunice Chang, PhD has received compensation for participation in committees of Genentech, Inc. and Grunenthal Group; Khaled Sarsour, PhD, MPH, has received travel expenses and compensation for participation in consultancies from Genentech Inc. and Grunenthal Group; Micki Kleieran, MD, is an employee of Genentech, Inc., a member of the Roche Group.

REFERENCES